Investigational drug · Phase 3
VC005
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
21
Any phase or sponsor naming "VC005"
First trial start
2025
Oct 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VC005", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Non-segmental Vitiligo
- Non-Segmental Vitiligo
- Atopic Dermatitis
- Active Ankylosing Spondylitis
- Alopecia Areata
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Ankylosing spondylitis · Alopecia areata · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "VC005" as an intervention, largest first.
- Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT06723080 · 480 participants (planned) · Start Dec 30, 2024 · Primary completion Aug 30, 2027
Drug: VC005 low dose group; VC005 high dose group and 1 more · For: Moderate to Severe Atopic Dermatitis
Sites: Nanjing, China
- Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.Pivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07172360 · 420 participants (planned) · Start Dec 26, 2025 · Primary completion Aug 30, 2027
Drug: VC005 tablets; VC005 Tablets Placebo · For: Active Ankylosing Spondylitis
Sites: Beijing, China
- Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic DermatitisPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07592585 · 360 participants (planned) · Start May 12, 2026 · Primary completion May 30, 2028
Drug: VC005; VC005 Placebo · For: Atopic Dermatitis
Sites: Nanjing, China
- Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.Pivotal-lookingCompleted
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT05814939 · 180 participants · Start Apr 26, 2023 · Primary completion May 11, 2024
Drug: VC005 tablets; Tofacitinib Citrate Tablets and 1 more · For: Active Ankylosing Spondylitis
Sites: Beijing, China
- Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT05997927 · 149 participants · Start Jul 20, 2023 · Primary completion Jul 9, 2024
Drug: VC005 tablets; VC005 Tablets Placebo · For: Moderate to Severe Atopic Dermatitis
Sites: Nanjing, China
- A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic DermatitisPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07598383 · 120 participants (planned) · Start Jun 1, 2026 · Primary completion Feb 22, 2027
Drug: VC005 group; VC005 Placebo group · For: Atopic Dermatitis
Sites: Hangzhou, China
- Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental VitiligoPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07172347 · 120 participants (planned) · Start Oct 31, 2025 · Primary completion Aug 30, 2027
Drug: VC005 tablets; VC005 Tablets Placebo · For: Non-segmental Vitiligo
Sites: Beijing, China
- Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia AreataPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07749716 · 120 participants (planned) · Start Aug 18, 2026 · Primary completion Dec 30, 2028
Drug: Drug: VC005 tablets; VC005 tablets and 1 more · For: Alopecia Areata
Sites: Beijing, China
- Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT06891040 · 118 participants · Start Apr 28, 2025 · Primary completion Oct 31, 2025
Drug: VC005 Placebo group; VC005 groups · For: Atopic Dermatitis
Sites: Nanjing, China
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07796191 · 84 participants (planned) · Start Sep 20, 2026 · Primary completion Nov 30, 2026
Drug: VC005 and verapamil; VC005 and probenecid and 1 more · For: Healthy Adult Participants
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-segmental Vitiligo
- SHR0302Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Non-segmental Vitiligo, Psoriatic Arthritis
- GIA632Phase 23 trials
Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
- ACT-777991Phase 21 trial
Idorsia Pharmaceuticals Ltd. · Non-Segmental Vitiligo
- EI-001Phase 21 trial
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Non-segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.